Prion-Like Spreading
Introduction
Prion Like Spreading is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
[@jucker2013] [@fitzpatrick2017]
Overview
Prion-like spreading refers to the template-directed, self-propagating transmission of misfolded protein aggregates between cells in the nervous system. In this mechanism, pathological protein conformers (seeds) are released from one cell, taken up by a neighboring cell, and recruit endogenous normal protein to adopt the same misfolded conformation — propagating pathology through neural circuits in a manner analogous to infectious prions. This concept has fundamentally reshaped understanding of neurodegenerative disease progression, explaining why pathology in Alzheimer's Disease], Parkinson's Disease], ALS, and other conditions follows stereotypical anatomical patterns ([Jucker & Walker, 2013](https://doi.org/10.1038/nature12481)). [@li2008]
[@fitzpatrick2017] [@schweighauser2020]
...Prion-Like Spreading
Introduction
Prion Like Spreading is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
[@jucker2013] [@fitzpatrick2017]
Overview
Prion-like spreading refers to the template-directed, self-propagating transmission of misfolded protein aggregates between cells in the nervous system. In this mechanism, pathological protein conformers (seeds) are released from one cell, taken up by a neighboring cell, and recruit endogenous normal protein to adopt the same misfolded conformation — propagating pathology through neural circuits in a manner analogous to infectious prions. This concept has fundamentally reshaped understanding of neurodegenerative disease progression, explaining why pathology in Alzheimer's Disease], Parkinson's Disease], ALS, and other conditions follows stereotypical anatomical patterns ([Jucker & Walker, 2013](https://doi.org/10.1038/nature12481)). [@li2008]
[@fitzpatrick2017] [@schweighauser2020]
Critically, the term "prion-like" distinguishes these mechanisms from true prion diseases: while the proteins share the capacity for templated misfolding and cell-to-cell spread, the neurodegenerative disease-associated aggregates are not naturally transmissible between individuals under normal circumstances (unlike PrPSc in Creutzfeldt-Jakob Disease or BSE). However, the molecular principles — seeded nucleation, conformational strains, and circuit-based propagation — are remarkably conserved. [@yang2024]
[@li2008] [@braak2003]
Molecular Mechanisms
Seeded Nucleation
The core mechanism of prion-like propagation follows a nucleation-polymerization model: [@holmes2013]
Seed formation: A small nucleus of misfolded protein (oligomer or short fibril) forms spontaneously or through cellular stress
Templated conversion: The seed recruits normal, soluble monomers and templates their conversion to the pathological conformation
Fibril elongation: Monomers are added to fibril ends, extending the aggregate
Fragmentation: Fibrils break into smaller fragments, generating new seeds and accelerating the process exponentially
Saturation: Eventually, the pool of available monomer becomes limitingThe rate-limiting step is primary nucleation (initial seed formation), which explains why sporadic diseases have long presymptomatic phases but then progress relatively rapidly once seeding reaches a threshold. [@soto2018]
Cell-to-Cell Transmission
Multiple pathways mediate the transfer of pathological seeds between cells: [@shahnawaz2020]
| Pathway | Mechanism | Evidence | Key [Proteins/proteins) | [@meisl2025]
|---------|-----------|----------|-------------|
| Synaptic transmission | Release at presynaptic terminal; uptake by postsynaptic neuron | Tau](/proteins/amyloid-beta) |
| Exosome-mediated | Seeds packaged in extracellular vesicles (30-150 nm) | Exosomal tau] and α-syn from patient CSF can seed aggregation | Tau, α-syn, PrP |
| Tunneling nanotubes | Direct cytoplasmic bridges between cells | Observed for tau, α-syn, and PrP transfer | Tau, α-syn, PrP |
| Bulk exocytosis/endocytosis | Non-vesicular release; uptake via macropinocytosis or receptor-mediated endocytosis | TDP-43], tau fibrils taken up by neurons] | All prion-like proteins |
| Heparan sulfate proteoglycans | Cell surface receptors for aggregate uptake | HSPG-dependent uptake of tau, α-syn fibrils | Tau, α-syn |
A crucial discovery: the same protein can adopt multiple distinct misfolded conformations (strains), each encoding different disease properties:
- Different strains have distinct biochemical signatures (protease resistance, seeding efficiency)
- Strains faithfully propagate their conformation to newly recruited monomers
- Different strains may underlie clinical heterogeneity within the same disease
- Cryo-EM has revealed the structural basis of strains at atomic resolution
Proteins with Prion-Like Behavior
Tau
Tau propagation is the best-characterized prion-like mechanism in AD:
- Braak staging: Tau pathology progresses stereotypically from entorhinal [cortex] → hippocampus] → association cortex → primary cortex, following neural connectivity
- Experimental evidence: Injection of AD-brain-derived tau into mouse hippocampus induces spreading pathology along connected circuits ([de Calignon et al., 2012](https://doi.org/10.1016/j.neuron.2011.11.033))
- Strain diversity: Cryo-EM structures reveal distinct tau folds in AD (paired helical filaments, straight filaments), Pick's disease, CBD, PSP, and CTE — each with a unique fibril structure ([Fitzpatrick et al., 2017](https://doi.org/10.1038/nature23002))
- Seeding activity: Tau seeds detectable in AD brain and CSF using seed amplification assays (SAA/RT-QuIC)
alpha-synuclein
alpha-synuclein spreading underlies Parkinson's Disease progression:
- Braak hypothesis: α-Synuclein Lewy pathology begins in the olfactory bulb and dorsal motor nucleus of the vagus, ascending through the brainstem to substantia nigra and cortex
- Host-to-graft transmission: Embryonic dopamine neuron grafts develop Lewy bodies 10-15 years after transplantation into PD patients — definitive evidence of host-to-graft spread
- Strain diversity: Cryo-EM reveals distinct α-synuclein folds — the "Lewy fold" (PD/DLB) versus the "MSA fold" (Multiple System Atrophy) — explaining clinical differences between synucleinopathies
- Diagnostic SAA: α-Synuclein seed amplification assay in CSF has >90% sensitivity and specificity for PD diagnosis; can distinguish PD from MSA strains
Amyloid-Beta
amyloid-beta exhibits prion-like properties, though its spreading pattern is less circuit-dependent:
- Intracerebral injection of AD brain homogenate induces Aβ pathology in APP] transgenic mice
- Iatrogenic transmission: Aβ pathology found in patients who received cadaveric growth hormone or dura mater grafts decades earlier
- Aβ seeds are resistant to formaldehyde fixation and autoclaving
- Different Aβ strains produce distinct plaque morphologies (diffuse vs. cored)
TDP-43
TDP-43 aggregation in ALS and Frontotemporal Dementia (FTD) shows prion-like features:
- TDP-43 seeds from FTLD subtypes produce distinct aggregation patterns in cell culture
- Cryo-EM reveals polymorphic TDP-43 fibril structures sharing an "amyloid key" motif (2024)
- Different TDP-43 strains show different susceptibility to protease digestion and distinct spreading patterns in vivo
- TDP-43 pathology can spread from the spinal cord to brain in ALS models
Huntingtin
Mutant huntingtin/proteins/huntingtin)] (mHTT) with expanded polyglutamine tracts can propagate:
- mHTT aggregates can be taken up by neurons and seed endogenous mHTT aggregation
- Spreading is observed in cell culture and Drosophila models
- The polyglutamine expansion itself confers seeding capacity
Cryo-EM Structures of Disease-Associated Fibrils
Recent cryo-EM advances (2017-2025) have revolutionized understanding of protein strains:
| Protein | Disease | Fold Name | Key Structural Feature |
|---------|---------|-----------|----------------------|
| Tau | AD | PHF/SF | C-shaped fold; R3-R4 repeat region |
| Tau | Pick's disease | Pick fold | Elongated, J-shaped |
| Tau | CBD | CBD fold | Four-layered; 3R+4R tau |
| Tau | PSP | PSP fold | Distinct from CBD despite clinical overlap |
| Tau | CTE | CTE fold | Unique hydrophobic cavity |
| α-Synuclein | PD/DLB | Lewy fold | Greek key motif |
| α-Synuclein | MSA | MSA fold | Two distinct protofilament interfaces |
| TDP-43 | ALS/FTLD | Amyloid key | Dagger-shaped fold with polymorphic protofilaments |
| Aβ | AD (type I/II) | Multiple folds | S-shaped; distinct in sporadic vs. familial AD |
These structures demonstrate that each disease has a characteristic fibril fold, potentially serving as the molecular basis for disease-specific clinical and pathological features.
Seed Amplification Assays (SAA)
Seed amplification assays exploit the prion-like seeding properties of pathological proteins for diagnosis:
- Principle: Patient biofluid (CSF, blood) containing minute amounts of seeds is incubated with recombinant substrate protein. Seeds template conversion, producing detectable amyloid signal (thioflavin T fluorescence)
- α-Synuclein SAA: FDA-recognized biomarker for PD; >92% sensitivity, >95% specificity from CSF; can distinguish PD from MSA strains based on kinetic parameters
- Tau SAA/RT-QuIC: Detecting tau seeds in AD CSF; 3R vs. 4R tau discrimination for Pick's vs. CBD/PSP
- TDP-43 SAA: Earlier-stage development; detecting TDP-43 seeds in ALS/FTD biospecimens
- Blood-based SAA: Active development area for non-invasive screening (2024-2025)
Therapeutic Implications
Anti-Seeding Immunotherapy
Antibodies designed to intercept seeds during cell-to-cell transfer:
- Anti-tau antibodies: Semorinemab, zagotenemab, bepranemab target extracellular tau species; clinical trials/clinical-trials) showed limited efficacy, suggesting intracellular propagation may be more important
- Anti-α-synuclein antibodies: [Prasinezumab showed modest slowing of motor progression in Phase 2 PD trial
- Anti-Aβ immunotherapy: lecanemab/therapeutics/lecanemab)] and donanemab target aggregated Aβ species that include seeds
Blocking Cellular Uptake
- HSPG antagonists (heparin mimetics) to block aggregate endocytosis
- Receptor decoys to intercept extracellular seeds
- Exosome release inhibitors (GW4869) to reduce vesicular seed transfer
Preventing Templated Conversion
- Small molecules that stabilize native protein conformation
- Molecular chaperone enhancers
- Antisense oligonucleotides (ASOs) to reduce the pool of convertible substrate protein (e.g., tau ASOs, α-synuclein ASOs in clinical trials)
Enhancing Seed Degradation
- Enhancing autophagy to degrade intracellular seeds
- Activating microglia
- Boosting proteasomal degradation of misfolded monomers
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/) — Biomedical literature database
- [Allen Brain Atlas](https://brain-map.org/) — Brain gene expression data
Background
The study of Prion Like Spreading has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying [mechanisms of neurodegeneration/mechanisms) and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Brain Atlas Resources
- Allen Human Brain Atlas: [Prion-Like Spreading expression search](https://human.brain-map.org/microarray/search/show?search_term=Prion-Like+Spreading)
- Allen Mouse Brain Atlas: [Prion-Like Spreading search](https://mouse.brain-map.org/search/index.html?query=Prion-Like+Spreading)
- Allen Cell Type Atlas: [Transcriptomic cell type reference](https://portal.brain-map.org/atlases-and-data/rnaseq)
- BrainSpan Developmental Transcriptome: [Prion-Like Spreading developmental expression](https://www.brainspan.org/rnaseq/search/index.html?search_term=Prion-Like+Spreading)
- [Alzheimer's Disease](/diseases/alzheimers-disease)](/diseases/alzheimers-disease)
- [Amyloid-Beta Aggregation](/proteins/amyloid-beta)
- [Tau Pathology](/mechanisms/tau-pathology)
- [Parkinson's Disease](/diseases/parkinsons-disease)](/genes/ar)
- [ALS](/diseases/als)
- [Frontotemporal Dementia](/diseases/frontotemporal-dementia)
- [Microglia](/cell-types/microglia)
- [neuroinflammation](/mechanisms/neuroinflammation)
- [Autophagy](/mechanisms/autophagy)
- [Proteostasis Failure](/mechanisms/als-rna-metabolism-and-proteostasis-failure)
References
[Unknown, Jucker M, Walker LC. Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature. 2013;501(7465):45-51. [DOI (2013)](https://doi.org/10.1038/nature12481)
[Fitzpatrick AWP, et al. Cryo-EM structures of tau filaments from, Alzheimer's Disease. Nature. 2017;547(7662):185-190. [DOI (2017)](https://doi.org/10.1038/nature23002)
[Li JY, et al. Lewy bodies in grafted, neurons in subjects with Parkinson's Disease suggest host-to-graft disease propagation. Nat Med. 2008;14(5):501-503. [DOI (2008)](https://doi.org/10.1038/nm1746)
[Schweighauser M, et al. Structures of α-synuclein filaments from, multiple system atrophy. Nature. 2020;585(7825):464-469. [DOI (2020)](https://doi.org/10.1038/s41586-020-2317-6)
[Yang Y, et al., Cryo-EM observation of the amyloid key structure of polymorphic TDP-43 amyloid fibrils. Nat Struct Mol Biol. 2024;31(2):328-336. [DOI (2024)](https://doi.org/10.1038/s41594-023-01180-0)
[Braak H, et al. Staging of brain pathology related to sporadic, Parkinson's Disease. Neurobiol Aging. 2003;24(2):197-211. [DOI (2003)](https://doi.org/10.1016/S0197-4580(02)
[Holmes BB, et al., Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. Proc Natl Acad Sci USA. 2013;110(33):E3138-E3147. [DOI (2013)](https://doi.org/10.1073/pnas.1301440110)
[Unknown, Soto C, Pritzkow S. Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases. Nat Neurosci. 2018;21(10):1332-1340. [DOI (2018)](https://doi.org/10.1038/s41593-018-0235-9)
[Shahnawaz M, et al. Discriminating α-synuclein strains in, Parkinson's Disease and Multiple System Atrophy. Nature. 2020;578(7794):273-277. [DOI (2020)](https://doi.org/10.1038/s41586-020-1984-7)
[Meisl G, et al., Beyond prion-like spreading in neurodegenerative disease. Alzheimers Dement. 2025. [DOI (2025)](https://doi.org/10.1002/alz.70789)